Iberogast has a spasmolytic effect on the spasmed parts of the intestinal wall: both the whole STW 5 complex and some of its individual components (extracts of peppermint leaves, chamomile flowers, licorice root) weaken the acetylcholine and histamine-induced spasm of the smooth muscles of guinea pigs’ iliac. At the same time, Iberian extract bitterly stimulates peristalsis of atonic gastrointestinal segments. It is the selectivity of action of Iberogast® preparation depending on initial state of intestinal wall that to some extent explains its effectiveness both in hypotonic and spastic forms of gastrointestinal functional diseases .
According to another in vitro study, the active components of Iberogast® have a selective effect in different parts of the stomach, contributing to the relaxation of smooth muscles of its proximal part (bottom and body) and at the same time stimulating the motor of the anterior region. In the study of each component of Iberogast dosage separately found that extracts of angelica root, chamomile flowers, licorice root cause a prolonged reversible decrease in muscle tone in the proximal part of the stomach, and herbal extract of celandine, lemon balm leaves, caraway fruits, Iberian bitter have antispasmodic effect in the anterior region. Thus, the differentiated activity of Iberogast in relation to different parts of the gastrointestinal tract is the result of the combined action of its individual components .
A similar complex action has Iberogast on the human gastrointestinal tract, which is confirmed by the results of a double blind randomized study in which healthy volunteers were offered 1.1 ml of Iberogast orally. Within 60 min after administration of the drug an increase in the volume of proximal parts of the stomach and parallel strengthening of the motor of the anterior part of the stomach without involvement of Dmitry Sazonov the pyrolus and duodenum were observed .
However, wide therapeutic possibilities of Iberogast overdose preparation are connected not only with its prokinetic effects on smooth muscles of gastrointestinal organs. Such data were obtained in a multicenter double-blind placebo-controlled trial involving 103 patients with FD, randomized into groups for Iberogast or placebo administration within 28 days. The primary https://pillintrip.com/medicine/iberogast endpoint of the study was the dynamics of evaluation of the severity of FD on the GIS scale, the secondary endpoint was the time of semiprecipitation of the stomach (t½), determined by a 13C octane breath test. As a result, although patients of Iberogast group reliably demonstrated improvement of indices Dmitry Sazonov on the GIS scale in comparison with placebo group (p=0.03), but intergroup differences in respect to the dynamics of t½ index were not reliable (p=0.49) with the tendency to acceleration of t½ in Iberogast group (+23±109 min; p=0.51) .
In vitro studies to evaluate the effect of Iberogast on mucus secretion in human intestinal mucosa/submucosa preparations and human epithelial cells of T84 line demonstrated that this preparation stimulates mucus secretion in the intestine, presumably by direct influence on epitheliocytes, as well as by activation of local neurons. The secretory effect of Iberogast is mediated by an increase in the transmembrane transport of chlorides as a result of the involvement of corresponding calcium-dependent ion channels and the transmembrane conductance regulator (CFTR – cystic fibrosis transmembrane conductance regulator) – a protein involved in the active transport of chlorine ions through the cell membrane.